Results 1 to 10 of about 247,670 (219)
Diffuse Large B-Cell Lymphoma.
New England Journal of Medicine, 2021 Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease, or both and require therapy ...
L. Sehn, G. Salles
semanticscholar +7 more sources
Cutaneous diffuse large B‐cell lymphoma [PDF]
Clinical Case Reports, 2018 Key Clinical Message Cutaneous diffuse large B‐cell lymphoma accounts for ~6% of all cutaneous lymphomas. It is associated with poor prognosis, and solitary lesions are relatively rare.
Filipa Duarte Ribeiro +3 more
doaj +3 more sources
Diffuse large B-Cell lymphoma-review
Journal of Medical Sciences, 2018 Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 30 percent of all NHL cases, involving both nodal and extra-nodal sites.
Rajeshwar Singh +6 more
doaj +2 more sources
Diffuse Large B-Cell Lymphoma [PDF]
Archives of Pathology & Laboratory Medicine, 2008 AbstractDiffuse large B-cell lymphoma is the most common lymphoma worldwide. Both morphologically and prognostically it represents a diverse spectrum of disease. Traditional morphologic subclassification often results in poor interobserver reproducibility and has not been particularly helpful in predicting outcome.
Kristin E, Hunt, Kaaren K, Reichard
+7 more sources
Haematologica, 2022 The sole distinguishing feature of follicular lymphoma grade 3B and diffuse large B-cell lymphoma is the growth pattern assessed by histopathology. Diffuse growth defines diffuse large B-cell lymphoma but the clinical relevance of this finding when ...
Karoline Koch +5 more
doaj +1 more source
Identification and validation of 5-methylcytosine-associated genes in diffuse large B-cell lymphoma
Heliyon, 2023 5-methylcytosine modifications play a significant role in carcinogenesis; however, studies exploring 5-methylcytosine-related genes in diffuse large B-cell lymphoma patients are lacking.
Cheng Xing +14 more
doaj +1 more source
Dermatology Online Journal, 2012 We present a 56-year-old man with a two-year history of erythematous nodules and plaques on the forehead, frontal aspect of the scalp, and left side of the neck. Histopathologic findings are compatible with a diagnosis of diffuse large B-cell lymphoma (DLBCL).
Mundi, Jyoti P +6 more
+7 more sources
Hematological Oncology, 2023 Abstract Large B‐cell lymphoma, the prototype of aggressive non‐Hodgkin lymphomas, is both the most common lymphoma and accounts for the highest global burden of lymphoma‐related deaths. For nearly 4 decades, the goal of treatment has been “cure”, first based on CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and ...
Allison Barraclough +3 more
openaire +3 more sources
Heliyon, 2023 Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive B-lymphocyte-derived malignant proliferative disease that is currently one of the leading causes of death in HIV patients.
Tao Peng fei, Hui Ru Xi, Min Hai yan
doaj +1 more source
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
New England Journal of Medicine, 2021 BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP.
H. Tilly +31 more
semanticscholar +1 more source